胃肠道感染期间使用抗生素增加肠易激综合征风险:系统评价与荟萃分析
抗生素使用者IBS总体合并发生率为26%,非使用者为20%,发生率比(IRR)为1.3(95%CI: 1.07-1.58;P=0.008);仅纳入胃肠道感染使用抗生素的研究中IRR为1.71(95%CI: 1.16-2.51;P=0.007),但异质性高(I2>90%)。
要点
- 抗生素使用与IBS风险升高相关,总体IRR为1.3(95%CI: 1.07-1.58)。
- 胃肠道感染期间使用抗生素者IBS风险更高,IRR为1.71(95%CI: 1.16-2.51)。
- 研究间异质性显著(I2>90%),结果解释需谨慎。
核心结论
- 抗生素使用与IBS发生风险增加相关,尤其在胃肠道感染后使用抗生素时风险更高。
- 研究间显著异质性降低了结果的效力,需进一步高质量研究明确该关系。
研究设计与样本
- 系统评价与荟萃分析,检索Medline、Embase、Scopus及会议摘要和引文追踪,截至2025年6月15日。
- 由2名评价员独立提取数据和质量评估,合并每1,000人年发生率及发生率比(IRR)与95%置信区间(CI),异质性以I2表示,并进行荟萃回归分析。
主要发现
- 抗生素使用者IBS总体合并发生率为26%,非使用者为20%,IRR为1.3(95%CI: 1.07-1.58;P=0.008)。
- 仅纳入胃肠道感染使用抗生素的研究中,抗生素使用者发生IBS的风险更高,IRR为1.71(95%CI: 1.16-2.51;P=0.007),研究间异质性高(I2>90%)。
- 地理区域、IBS诊断标准和研究质量与估计效应相关,解释了观察到的异质性。
临床怎么用
- 在胃肠道感染患者中处方抗生素时,需权衡IBS风险,尤其对于高风险人群。
- 对使用抗生素后的患者,可关注IBS相关症状的监测与随访。
局限性
- 研究间显著异质性(I2>90%)降低了结果的效力。
- 地理区域、IBS诊断标准和研究质量等因素影响估计效应,需进一步高质量研究澄清关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction which negatively affects patients' quality of life. It has been hypothesized that changes in gut microbiota composition and function evoked by antibiotic use represent a trigger for IBS development. This systematic review and meta-analysis aimed to assess the incidence of IBS after antibiotic use. METHODS: Medline, Embase, and Scopus, along with relevant conference abstracts and citation tracking were searched up to June 15th, 2025. Studies that reported new diagnoses of IBS in patients with documented antibiotic exposure vs controls without antibiotic exposure were included. Data extraction and quality assessment were performed independently by 2 reviewers. Pooled incidence rates per 1,000 person-years, along with incidence rate ratios (IRRs) with 95% confidence intervals (CI) were pooled; heterogeneity was expressed as I2 . Metaregression analysis was performed to assess the impact of confounding covariates. RESULTS: Thirty-one studies comprising a total of 422,350 patients (244,632 antibiotic users and 177,718 nonusers) were included. The overall pooled incidence of IBS was 26% in antibiotic users compared with 20% in nonusers, resulting in an IRR of 1.3 (95% CI: 1.07-1.58; P = 0.008). In sensitivity analyses including only studies in which antibiotics were used for gastrointestinal infections, the risk of developing IBS was higher for antibiotic users (IRR: 1.71; 95% CI: 1.16-2.51; P = 0.007), with high heterogeneity ( I2 > 90%) among studies. Geographical area, criteria for IBS diagnosis and study quality were associated with estimated effects, explaining the observed heterogeneity. DISCUSSION: Antibiotic use is associated with increased risk of developing IBS, especially after gastrointestinal infections. However, the significant study heterogeneity reduces the power of our results, suggesting that further high-quality research is needed to clarify this relationship.
引用
- Colecchia L, Marasco G, Capelli C, et al. Antibiotic Use During Gastrointestinal Infections Increases the Risk of Developing Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2026. PMID: 41860116. doi:10.14309/ajg.0000000000004001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。